Unlocking access to a high cost rare disease treatment
The evaluation and reimbursement process for ultra-rare disease treatments in the UK is complex. It can delay access to life-changing treatments for patients who cannot afford to wait.
We helped our client, a small pharmaceutical company, to identify the key decision-takers and uncover barriers that were impeding a positive outcome for their medicine. By forging strong relationships and presenting viable options to move the process forward, we were able to secure a positive evaluation and reimbursement decision that met the needs of patients, the company and the NHS.